Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2023)
Historic Free Cash Flow for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to -$18.1 million.
- Cullinan Therapeutics' Free Cash Flow rose 2990.14% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.5 million, marking a year-over-year decrease of 523.17%. This contributed to the annual value of -$145.3 million for FY2024, which is 804.56% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Free Cash Flow of -$18.1 million as of Q4 2023, which was up 2990.14% from -$34.1 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Free Cash Flow registered a high of -$1.5 million during Q1 2021, and its lowest value of -$54.6 million during Q3 2022.
- Moreover, its 4-year median value for Free Cash Flow was -$17.2 million (2021), whereas its average is -$21.0 million.
- As far as peak fluctuations go, Cullinan Therapeutics' Free Cash Flow skyrocketed by 6980.87% in 2021, and later plummeted by 134607.26% in 2022.
- Over the past 4 years, Cullinan Therapeutics' Free Cash Flow (Quarter) stood at -$9.4 million in 2020, then tumbled by 60.79% to -$15.2 million in 2021, then tumbled by 70.49% to -$25.9 million in 2022, then grew by 29.9% to -$18.1 million in 2023.
- Its last three reported values are -$18.1 million in Q4 2023, -$34.1 million for Q3 2023, and -$31.1 million during Q2 2023.